Speaking the same language: Treatment outcome definitions for multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 6, 2005, Pages 640-645

  Laserson, Kayla F ^a   Thorpe, L E ^a,b   Leimane, V ^c   Weyer, K ^d   Mitnick, C D ^e   Riekstina, V ^c   Zarovska, E ^c   Rich, M L ^f   Fraser, H S F ^f   Alarcon E ^g,h   Cegielski, J P ^a   Grzemska, M ⁱ   Gupta, R ⁱ   Espinal, M ⁱ  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^c State Agency of Tuberculosis and Lung Diseases   (Latvia)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e HARVARD MEDICAL SCHOOL   (United States)

^f PARTNERS IN HEALTH   (United States)

^g Natl Tuberculosis Control Program   (Peru)

^h INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cohort analysis; Definitions; Multidrug resistant TB; Treatment outcome

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; THIOAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; COHORT ANALYSIS; DIRECTLY OBSERVED THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SPUTUM SMEAR; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

COHORT STUDIES; DIRECTLY OBSERVED THERAPY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; TERMINOLOGY; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 20444476136     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Dye C, Espinal M S, Watt C J, Mbiaga C, Williams B. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
2. World Health Organization. Anti-tuberculosis drug resistance in the world: third global report. The WHO/IUTALD global project on anti-tuberculosis drug resistance surveillance 1999-2002. Geneva, Switzerland: WHO, 2004.
3. Gupta R, Espinal M A. DOTS-Plus: preliminary results and emerging issues. WHO/CDS/TB/2002.307. Geneva, Switzerland: WHO, 2002.
4. World Health Organization. Guidelines for establishing DOTS-Plus Pilot Projects for the management of multidrug-resistant tuberculosis (MDR-TB). Arnadottir T, Gupta R, eds. WHO/CDS/TB/2000.278. Geneva, Switzerland: WHO, 2000.
5. Gupta R, Kim J Y, Espinal M A, et al. Responding to market failures in tuberculosis control. Science 2001; 293: 1049-1051.
6. Gupta R, Cegielski J P, Espinal M A, et al. Increasing transparency in partnerships for health - introducing the Green Light Committee. Trop Med Int Health 2002; 7: 970-976.
7. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. WHO/CDSATB/2003.313. Geneva, Switzerland: WHO, 2003.
8. World Health Organization. WHO Report 2002: global tuberculosis control. WHO/CDS/TB/2002.295. Geneva, Switzerland: WHO, 2002.
9. Fox W, Ellard G A, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (10 Suppl 2): S231-S279.
10. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5: 213-215.
11. Gibbons R J, Smith S, Antman E, American College of Cardiology, American Heart Association. American College of Cardiology/American Heart Association clinical practice guidelines: Part I: where do they come from? Circulation 2003; 107: 2979-2986.
12. Avendano M, Goldstein R S. Multidrug-resistant tuberculosis: long-term follow-up of 40 non-HIV-infected patients. Can Respir J 2000; 7: 383-389.
13. Bahrmand A R, Velayati A A, Bakayev V V. Treatment monitoring and prevalence of drug-resistance in tuberculosis patients in Tehran. Int J Tuberc Lung Dis 2000; 4: 544-549.
14. Davies G R, Pillay M, Sturm A W, Wilkinson D. Emergence of multidrug-resistant tuberculosis in a community-based directly observed treatment programme in rural South Africa. Int J Tuberc Lung Dis 1999; 3: 799-804.
15. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcomes of multidrug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593.
16. Franzetti F, Gori A, Iemoli E, et al. Outcome of multidrug-resistant tuberculosis in human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 553-560.
17. Frieden T R, Sterling T, Pablos-Mendez A, Kilburn J O, Cauthen G M, Dooley S W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
18. Frieden T R, Sherman L F, Maw K L, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis. J Am Med Assoc 1996; 276: 1229-1235.
19. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
20. Hersi A, Elwood K, Cowie R, Kunimoto D, Long R. Multidrug-resistant tuberculosis in Alberta and British Columbia, 1989 to 1998. Can Respir J 1999; 6: 155-160.
21. Kim S J, Bai G H, Hong Y P. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1997; 1: 302-308.
22. Lambregts-van Weezenbeek CSB, Jansen H M, Nagelkerke NJD, van Klingeren B, Veen J. Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: risk factors and treatment outcome. Int J Tuberc Lung Dis 1998; 2: 288-295.
23. Lan N T N, Iademarco M F, Binkin N J, Tung L B, Quy H T, Co N V. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2001; 5: 575-578.
24. Lockman S, Kruuner A, Binkin N J, et al. Clinical outcomes of Estonian patients with primary multidrug-resistant tuberculosis versus drug-susceptible tuberculosis. Clin Infect Dis 2001; 32: 373-380.
25. Mangunnegoro H, Hudoyo A. Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia. Chemotherapy 1999; 45: 19-25.
26. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
27. Narita M, Alonso P, Lauzardo M, Hollender E S, Pitchenik A E, Askin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001; 120: 343-348.
28. Park M M, Davis A L, Schluger N W, Cohen H, Rom W N. Outcome of multidrug-resistant tuberculosis patients, 1983-1993. Am J Respir Crit Care Med 1996; 153: 317-324.
29. Park S K, Kim C T, Song S D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to INH and RIF. Int J Tuberc Lung Dis 1998; 11: 877-884.
30. Saenghirunvattana S, Vathesatogkit P, Charoenpan P, Kiatboonsri S, Aeursudkij B. MDR-TB: response to treatment. J Med Assoc Thai 1996; 79: 602-603.
31. Salomon N, Perlman D C, Priedman P, Buchstein S, Kreisworth B N, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1245-1252.
32. Schaaf H S, Botha P, Beyers N, et al. The 5-year outcome of multidrug-resistant tuberculosis patients in the Cape Province of South Africa. Trop Med Int Health 1996; 1: 718-722.
33. Suo J, Yu M, Lee C, Chiang C, Lin T. Treatment of multidrug-resistant tuberculosis in Taiwan. Chemotherapy 1996; 42: 20-23.
34. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
35. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
36. Turett G S, Telzak E E, Torian L V, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1238-1244.
37. Yew W W, Chan K C, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-751.
38. Zhang L. Treatment of multidrug-resistant tuberculosis in China. Chemotherapy 1996; 42: 16-19.
39. World Health Organization. Laboratory services in tuberculosis control. Part III: Culture. WHO/TB/98.258. Geneva, Switzerland: WHO, 1998.
40. Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Management of tuberculosis. A guide for low-income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
41. Wilkinson D. Sputum microscopy at 2 and 3 months. Int J Tuberc Lung Dis 1998; 2: 862-863.
42. Zhao F S, Levy M H, Wen S. Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Int J Tuberc Lung Dis 1997; 1: 570-572.
43. Davies G R, Connolly C, Sturm A W, McAdam K P, Wilkinson D. Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa. AIDS 1999; 13: 811-817.
44. Sterling T R, Lehman H P, Frieden T R. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. Br Med J 2003; 326: 574.